secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001493152-26-013653
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx reports 2025 revenue of $1.1M from RenovoCath; net loss $11.2M; cash $13M after $10M financing
--------------------------------------------------------------------------------

- FY2025 revenue $1.1M vs $43K in 2024; first full year of RenovoCath commercialization; cost of revenue $327K, gross profit $796K.
- Net loss $11.2M ($0.32 diluted EPS) vs $8.8M ($0.40) in 2024; R&D spend $6.3M, SG&A $7.0M.
- Phase III TIGeR-PaC trial: 104 patients randomized (target 114), 72 deaths; enrollment completion expected mid-2026, final data 2027.
- 12 U.S. cancer centers actively using RenovoCath as of Feb 2026; 33 centers in pipeline; $400M peak U.S. TAM for device.
- Appointed Mark Voll as CFO in Feb 2026; closed $10M private placement (net $9.2M) on Mar 20, 2026; cash $13M on hand.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000149315226013653/0001493152-26-013653-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000149315226013653/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-013653

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer